Emmanuel Babeau - Sanofi ADR Independent Director

SNY Stock  USD 48.60  0.94  1.90%   

Director

Mr. Emmanuel Babeau has held the position of Independent Director of Sanofi S.A. since May 2, 2018. He is Member of the Audit Committee of the Company. Since April 2013, he was Deputy Chief Executive Officer in charge of Finance Legal Affairs of Schneider Electric, office renewed on April 25, 2017. He began his career at Arthur Andersen in late 1990. In 1993, he joined Pernod Ricard as an Internal Auditor. He was appointed Head of Internal Audit, Corporationrationrate Treasury and Consolidation in 1996. He subsequently held several executive positions at Pernod Ricard, notably outside France, among which he served as Finance and Administrative Director Spain subsidiary in 1997. In 2001, he rejoined Pernod Ricard headoffices in Paris to hold position of Vice President, Development, in charge of the integration of Seagram. Progressing fast, he was appointed CFO in 2003 and Group Deputy Managing Director of Finance in 2006, supervising Finance, Information Systems and Industry Administrations. He joined Schneider Electric in 2009 as Executive Vice President Finance and Member of the Management Board of Schneider Electric since 2018.
Age 51
Tenure 6 years
Address 46, avenue de la Grande Armée,, Paris, France, 75017
Phone33 1 53 77 40 00
Webhttps://www.sanofi.com
Emmanuel Babeau is graduated from the Ecole superieure de commerce de Paris, and also holds a postgraduate diploma in finance and accounting . He currently acts as Director of Schneider Electric Industries SAS ; Member of the Supervisory Board of Aster Capital Partners SAS, Schneider Electric Energy Access representing Schneider Electric Industries SAS and Director of Sodexo, among others.

Sanofi ADR Management Efficiency

The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.17 in 2024. Return On Assets is likely to rise to 0.08 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 77.3 B in 2024, whereas Total Assets are likely to drop slightly above 88.2 B in 2024.
The company has 18.42 B in debt with debt to equity (D/E) ratio of 0.3, which may show that the company is not taking advantage of profits from borrowing. Sanofi ADR has a current ratio of 1.27, demonstrating that it may have difficulties to pay its financial commitments when the payables are due. Debt can assist Sanofi ADR until it has trouble settling it off, either with new capital or with free cash flow. So, Sanofi ADR's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sanofi ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sanofi to invest in growth at high rates of return. When we think about Sanofi ADR's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Ulrich SchmidtAlcoa Corp
65
Samuel PalmisanoExxon Mobil Corp
68
Jack BovenderBank Of America
74
John FrankChevron Corp
64
Suzanne SitherwoodAlcoa Corp
60
Julie RichardsonAlcoa Corp
N/A
Paul WalshMcDonalds
65
Alex GorskyInternational Business Machines
60
Charles GiffordBank Of America
72
Marissa MayerWalmart
44
Timothy FlynnWalmart
64
Margaret GeorgiadisMcDonalds
56
Richard DaleyThe Coca Cola
75
Robert KotickThe Coca Cola
57
Samuel NunnThe Coca Cola
78
Mark FieldsInternational Business Machines
55
Henrietta ForeExxon Mobil Corp
67
Kathryn FullerAlcoa Corp
73
Joseph HooleyExxon Mobil Corp
63
Jim WaltonWalmart
65
Dambisa MoyoChevron Corp
52
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 95442 people. Sanofi ADR (SNY) is traded on NASDAQ Exchange in USA. It is located in 46, avenue de la Grande Armée,, Paris, France, 75017 and employs 86,088 people. Sanofi ADR is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Sanofi ADR Leadership Team

Elected by the shareholders, the Sanofi ADR's board of directors comprises two types of representatives: Sanofi ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi ADR's management team and ensure that shareholders' interests are well served. Sanofi ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee
Emmanuel Babeau, Independent Director
Roy Papatheodorou, Executive Counsel
Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team
Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee
Dieter Weinand, Executive Vice President Member of the Executive Board
Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team
Eva SchaeferJansen, Head Relations
Fabienne Lecorvaisier, Director
George Grofik, Vice President of Investor Relations
Karen Linehan, Executive VP of Legal Affairs and General Counsel
Klaus Pohle, Independent Director
John Reed, President - Global Research & Development, Member of the Executive Committee
Bernard Charles, Independent Director
Melanie Lee, Independent Director
Madeleine Roach, Executive Operations
Pierre Chancel, Senior Marketing
Christophe Babule, Director
Bonnie Bassler, Director
Thomas Suedhof, Independent Director
Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee
Laurent Attal, Director
JeanRene Fourtou, Independent Director
JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee
Josephine Fubara, Chief Care
Christian Mulliez, Director
Robert Castaigne, Independent Director
Laurent Gilhodes, Principal Accounting
Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team
Uwe Bicker, Independent Director
Josep Catlla, Head Communications
Claudie Haignere, Independent Director
Olivier Brandicourt, CEO, Director and Member of Strategy Committee
Paul Hudson, CEO Director
Bruno Mnard, Chief officer
Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team
Dante Beccaria, Global VP
Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee
William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee
Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team
David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe
Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team
Diane Souza, Independent Director
Carole Piwnica, Independent Director
Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team
Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee
Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team
Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team
DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee
Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team
Igor Landau, Director
Patrick Kron, Independent Director
Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee
Gerard Kemmel, Independent Director
SuetFern Lee, Independent Director
Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team
David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team
Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee
Suet Lee, Independent Director

Sanofi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Sanofi ADR Investors Sentiment

The influence of Sanofi ADR's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Sanofi. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Sanofi ADR's public news can be used to forecast risks associated with an investment in Sanofi. The trend in average sentiment can be used to explain how an investor holding Sanofi can time the market purely based on public headlines and social activities around Sanofi ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Sanofi ADR's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Sanofi ADR's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Sanofi ADR's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Sanofi ADR.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sanofi ADR in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sanofi ADR's short interest history, or implied volatility extrapolated from Sanofi ADR options trading.

Currently Active Assets on Macroaxis

When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Sanofi Stock analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Transaction History
View history of all your transactions and understand their impact on performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.217
Dividend Share
3.76
Earnings Share
2.33
Revenue Per Share
18.388
Quarterly Revenue Growth
0.029
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.